Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Fox TA, Kirkwood AA, Enfield L, O'Reilly M, Arulogun S, D'Sa S, O'Nions J, Kavi J, Vitsaras E, Townsend W, Burns SO, Gohil SH, Cwynarski K, Thomson KJ, Noursadeghi M, Heyderman RS, Rampling T, Ardeshna KM, McCoy LE, Morris EC. Fox TA, et al. Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21. Br J Haematol. 2021. PMID: 34545952 Free PMC article. No abstract available.
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K. Peggs KS, et al. Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009. Biol Blood Marrow Transplant. 2003. PMID: 12720218 Free article. Clinical Trial.
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
D'Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M, White H, Hale G, Waldmann H, Goldstone A, Mackinnon S, Yong K. D'Sa S, et al. Br J Haematol. 2003 Oct;123(2):309-22. doi: 10.1046/j.1365-2141.2003.04612.x. Br J Haematol. 2003. PMID: 14531914 Free article. Clinical Trial.
Treatment for lymph node tuberculosis.
Sellar RS, Corbett EL, D'Sa S, Linch DC, Ardeshna KM. Sellar RS, et al. BMJ. 2010 Mar 10;340:c63. doi: 10.1136/bmj.c63. BMJ. 2010. PMID: 20219818 No abstract available.
[Therapy of lymph node tuberculosis].
Sellar RS, Corbett EL, D'Sa S, Linch DC, Ardeshna KM. Sellar RS, et al. Praxis (Bern 1994). 2010 Aug 25;99(17):1043-6. doi: 10.1024/1661-8157/a000242. Praxis (Bern 1994). 2010. PMID: 20737396 German. No abstract available.
Guidelines for the diagnosis and management of multiple myeloma 2011.
Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J; Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Bird JM, et al. Br J Haematol. 2011 Jul;154(1):32-75. doi: 10.1111/j.1365-2141.2011.08573.x. Epub 2011 May 14. Br J Haematol. 2011. PMID: 21569004 Free article. Review. No abstract available.
144 results